46 completed, 8 recruiting, 7 terminated, 5 withdrawn. 20 Phase 2, 19 Phase 1, 13 Phase 3, 11 Phase 4, 4 Not applicable.
Follow posaconazole: new trials by email Literature Review of posaconazole trials Research Report on posaconazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome Monzosertib, Posaconazole, Isavuconazole - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 42 | 2027-01-01 | 2026-08-21 |
| Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) LAmB B, Posaconazole, World Health Organization (WHO)-recommended SOC - Histoplasmosis | Phase 3 | Not yet recruiting | University of Minnesota | 664 | 2026-11-01 | 2026-10-02 |
| Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML AMX-883, Posaconazole - Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome | Phase 1 | Recruiting | Amphista Therapeutics Ltd | 54 | 2026-09-16 | 2026-10-15 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression AZD3632, Posaconazole - Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 84 | 2026-01-09 | 2026-07-20 |
| Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer Posaconazole, Nab-paclitaxel, Carboplatin - Breast Cancer | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 72 | 2025-05-01 | 2026-02-25 |
| Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole - Mucormycosis in Hematologic Malignancies | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2025-03-25 | 2025-09-22 | |
| Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI) Posaconazole - Hematologic Malignancy | Phase 2 | Recruiting | Nantes University Hospital | 30 | 2024-11-08 | 2026-01-26 |
| Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis transbronchoscopic interventional debridement - Pulmonary Mucormycosis | Not applicable | Unknown | Beijing Tsinghua Chang Gung Hospital | 30 | 2024-07-30 | 2024-07-11 |
| Azoles Targeting Recurrent High Grade Gliomas Ketoconazole (KCZ), Posaconazole (PCZ) - Brain Tumor, Recurrent, Cancer, Advanced | Early Phase 1 | Not yet recruiting | University Health Network, Toronto | 30 | 2024-06-01 | 2024-03-08 |
| Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD Posaconazole tablet - Invasive Fungal Disease, Graft Versus Host Disease | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2023-08-01 | 2024-11-20 | |
| Pilot Study of Posaconazole in Crohn's Disease Posaconazole Delayed Release Oral Tablet, Matching Placebo Tablet - Crohn Disease, CARD9 S12N Risk Allele | Phase 4 | Terminated | Cedars-Sinai Medical Center | 10 | 2022-08-17 | 2026-02-24 |
| Amphotericin Versus Posaconazole for Pulmonary Mucormycosis Posaconazole 600 mg followed by posaconazole 300 mg once daily, Liposomal Amphotericin B - Mucormycosis; Pulmonary (Etiology) | Phase 2 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 82 | 2022-07-01 | 2026-05-22 |
| Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial Posaconazole Pill - Glioblastoma, Glioblastoma Multiforme | Early Phase 1 | Terminated | Milton S. Hershey Medical Center | 7 | 2022-05-13 | 2026-01-23 |
| Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) Posaconazole IV 6 mg/kg, Posaconazole PFS 6 mg/kg - Invasive Fungal Infection | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 40 | 2022-02-22 | 2026-08-12 |
| A Study of BGB-11417 in Participants With Myeloid Malignancies BGB-11417, Azacitidine, Posaconazole - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 260 | 2021-05-24 | 2026-09-14 |
| Azole-echinocandin Combination Therapy for Invasive Aspergillosis Azole, Anidulafungin - Invasive Aspergillosis | Phase 3 | Terminated | Erasmus Medical Center | 66 | 2021-05-11 | 2024-05-07 |
| Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease Ibrutinib, ECG, PFT's - Chronic GVHD | Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2021-05-10 | 2026-01-23 |
| A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection Posaconazole 100 MG [Noxafil], Posaconazole 40 MG/ML - Cystic Fibrosis, Aspergillosis | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 135 | 2021-04-22 | 2021-07-19 |
| Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients Oral Posaconazole tablets - Pulmonary Fungal Infection | Completed | Institute of Hematology & Blood Diseases Hospital, China | 360 | 2021-02-08 | 2026-02-11 |
Showing 20 of 76. Sign in to see all of them.
Mycoses (24) · Leukemia, Myeloid, Acute (13) · Myelodysplastic Syndromes (7) · Aspergillosis (6) · Invasive Fungal Infections (6) · Candidiasis (4) · Hematologic Neoplasms (4) · HIV Infections (3) · AIDS-Related Opportunistic Infections (2) · Anemia, Aplastic (2) · Brain Neoplasms (2) · Candidiasis, Oral (2) · Chagas Disease (2) · Cystic Fibrosis (2) · Granulomatous Disease, Chronic (2)
Merck Sharp & Dohme LLC (23) · Radboud University Medical Center (4) · Institute of Hematology & Blood Diseases Hospital, China (3) · M.D. Anderson Cancer Center (3) · F2G Ltd (2) · Hoffmann-La Roche (2) · Schering-Plough (2) · AbbVie (1) · Amphista Therapeutics Ltd (1) · Astellas Pharma Global Development, Inc. (1) · AstraZeneca (1) · Bambino Gesù Hospital and Research Institute (1) · Bayside Health (1) · BeOne Medicines (1) · Beijing Tsinghua Chang Gung Hospital (1)
United States (24) · France (10) · Belgium (8) · Netherlands (8) · China (7) · Italy (7) · Germany (6) · Canada (5) · South Korea (5) · Spain (5) · United Kingdom (5) · Australia (4) · Greece (3) · Israel (3) · Mexico (3)
David M Burger, PharmD PhD (2) · Abhishek Maiti, MBBS (1) · Adilia Warris, Prof (1) · Aiming Pang, doctor (1) · Alireza Mansouri, MD (1) · Bart Rijnders, MD, PhD (1) · Catherine Hardalo, MD (1) · David Bell, MD (1) · Dwight E Yin, MD, MPH (1) · Gelareh Zadeh, MD, PhD (1) · Genovefa Papanicolaou, MD (1) · Gil Y Melmed, MD (1)
PMID 18813103, PMID 20667889, PMID 21772229, PMID 21967490, PMID 22290953, PMID 22324990, PMID 22814329, PMID 23924680, PMID 24733463, PMID 24827034, PMID 25049247, PMID 26612870, PMID 28161120, PMID 28231946, PMID 28961714, PMID 29339097, PMID 29581122, PMID 30361262, PMID 30913226, PMID 31971567, PMID 32319040, PMID 32682946, PMID 33438477, PMID 33549194, PMID 34050768, PMID 35046058, PMID 35063965, PMID 35167031, PMID 35829925, PMID 35861778, PMID 36007102, PMID 36906440, PMID 37676612, PMID 37773627, PMID 38828958, PMID 39133921, PMID 39378343, PMID 39800852, PMID 40044655, PMID 40830172, PMID 40913104, PMID 41589852, PMID 42494994
2018 (3), 2019 (3), 2014 (2), 2023 (2), 2025 (2), 2008 (1), 2016 (1), 2017 (1), R01DK125495 (1), R03CA255992 (1)